Cargando…

Effect of gallium nitrate on the expression of osteoprotegerin and receptor activator of nuclear factor-κB ligand in osteoblasts in vivo and in vitro

Osteoporosis is characterized by the progressive loss of bone mass and the micro-architectural deterioration of bone tissue, leading to bone fragility and an increased risk of fracture. Gallium has demonstrated efficacy in the treatment of several diverse disorders that are characterized by accelera...

Descripción completa

Detalles Bibliográficos
Autores principales:	LI, JINGWU, WANG, GUANG-BIN, FENG, XUE, ZHANG, JING, FU, QIN
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2016
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4686028/ https://www.ncbi.nlm.nih.gov/pubmed/26647856 http://dx.doi.org/10.3892/mmr.2015.4588

Ejemplares similares

Platelet-rich fibrin increases the osteoprotegerin/receptor activator of nuclear factor-κB ligand ratio in osteoblasts
por: Sumida, Ryuta, et al.
Publicado: (2019)

Mycobacterium tuberculosis 10-kDa co-chaperonin regulates the expression levels of receptor activator of nuclear factor-κB ligand and osteoprotegerin in human osteoblasts
por: ZHANG, YUANYU, et al.
Publicado: (2015)

Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss
por: Trouvin, Anne-Priscille, et al.
Publicado: (2010)

Osteoprotegerin/receptor activator of nuclear factor-κB ligand are involved in periodontitis-promoted vascular calcification
por: Jiao, Mengyu, et al.
Publicado: (2022)

Effects of alpha-calcitonin gene-related peptide on osteoprotegerin and receptor activator of nuclear factor-κB ligand expression in MG-63 osteoblast-like cells exposed to polyethylene particles
por: Xu, Jie, et al.
Publicado: (2010)

Soluble receptor activator of nuclear factor κB ligand/osteoprotegerin ratio is increased in systemic lupus erythematosus patients
por: Carmona-Fernandes, Diana, et al.
Publicado: (2011)

Isoliquiritigenin Inhibits Metastatic Breast Cancer Cell-induced Receptor Activator of Nuclear Factor Kappa-B Ligand/Osteoprotegerin Ratio in Human Osteoblastic Cells
por: Lee, Sun Kyoung, et al.
Publicado: (2015)

IGF-I increases markers of osteoblastic activity and reduces bone resorption via osteoprotegerin and RANK-ligand
por: Guerra-Menéndez, Lucia, et al.
Publicado: (2013)

Local Production of Osteoprotegerin by Osteoblasts Suppresses Bone Resorption
por: Cawley, Keisha M., et al.
Publicado: (2020)

Osteoprotegerin, Soluble Receptor Activator of Nuclear Factor-κB Ligand, and Subclinical Atherosclerosis in Children and Adolescents with Type 1 Diabetes Mellitus
por: Lambrinoudaki, Irene, et al.
Publicado: (2013)

Role of Osteoprotegerin and Receptor Activator of Nuclear Factor-κB Ligand in Bone Loss Related to Advanced Chronic Obstructive Pulmonary Disease
por: Ugay, Ludmila, et al.
Publicado: (2016)

Increase in receptor activator of nuclear factor κB ligand/osteoprotegerin ratio in peri-implant gingiva exposed to Porphyromonas gingivalis lipopolysaccharide
por: Shuto, Takahiro, et al.
Publicado: (2016)

Imbalance of osteoprotegerin/receptor activator of nuclear factor-κB ligand and oxidative stress in patients with obstructive sleep apnea-hypopnea syndrome
por: Ma, Xiao-Rong, et al.
Publicado: (2019)

Receptor activator of nuclear factor kappa B ligand and osteoprotegerin levels in gingival crevicular fluid
por: Sarlati, Fatemeh, et al.
Publicado: (2012)

Validity of Osteoprotegerin and Receptor Activator of NF-κB Ligand for the Detection of Bone Metastasis in Breast Cancer
por: Elfar, Gamal A., et al.
Publicado: (2017)

Expression of osteoprotegerin and osteoprotegerin ligand in giant cell tumor of bone and its clinical significance
por: YU, XIUCHUN, et al.
Publicado: (2013)

Thermal Plasma Synthesis of Crystalline Gallium Nitride Nanopowder from Gallium Nitrate Hydrate and Melamine
por: Kim, Tae-Hee, et al.
Publicado: (2016)

Tramadol enhances PGF(2α)-stimulated osteoprotegerin synthesis in osteoblasts
por: Kim, Woo, et al.
Publicado: (2020)

The Role of Osteoprotegerin and Its Ligands in Vascular Function
por: Rochette, Luc, et al.
Publicado: (2019)

Correlation of plasma osteoprotegerin (OPG) and receptor activator of the nuclear factor κB ligand (RANKL) levels with clinical risk factors in patients with advanced carotid atherosclerosis
por: Giaginis, Constantinos, et al.
Publicado: (2012)

Salivary soluble receptor activator of nuclear factor kappa B ligand/osteoprotegerin ratio in periodontal disease and health
por: Tabari, Zahra Alizadeh, et al.
Publicado: (2013)

Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers
por: Widschwendter, Martin, et al.
Publicado: (2015)

Pyoverdine Inhibitors and Gallium Nitrate Synergistically Affect Pseudomonas aeruginosa
por: Kang, Donghoon, et al.
Publicado: (2021)

Serum levels of osteoprotegerin and receptor activator of nuclear factor -κB ligand in children with early juvenile idiopathic arthritis: a 2-year prospective controlled study
por: Lien, Gunhild, et al.
Publicado: (2010)

(99)Tc-MDP-induced human osteoblast proliferation, differentiation and expression of osteoprotegerin
por: Chen, Jie, et al.
Publicado: (2017)

Effect of Breastfeeding on Serum Osteoprotegerin and Soluble Receptor Activator of Nuclear Factor-Kappa B Ligand in Full Term Neonates
por: Rafeey, Mandana, et al.
Publicado: (2013)

The Ligand for Osteoprotegerin (OPGL) Directly Activates Mature Osteoclasts
por: Burgess, Teresa L., et al.
Publicado: (1999)

The Effect of Gallium Nitrate on Arresting Blood Flow from a Wound
por: Goodley, Paul H., et al.
Publicado: (2011)

Role of osteoprotegerin/receptor activator of nuclear factor kappa B/receptor activator of nuclear factor kappa B ligand axis in nonalcoholic fatty liver disease
por: Pacifico, Lucia, et al.
Publicado: (2018)

Roles of osteoprotegerin in endocrine and metabolic disorders through receptor activator of nuclear factor kappa-B ligand/receptor activator of nuclear factor kappa-B signaling
por: Zhang, Luodan, et al.
Publicado: (2022)

Production of Soluble Receptor Activator of Nuclear Factor Kappa-Β Ligand and Osteoprotegerin by Apical Periodontitis Cells in Culture and Their Modulation by Cytokines
por: Duka, Miloš, et al.
Publicado: (2019)

Expression of osteoprotegerin and RANK ligand in breast cancer bone metastasis.
por: Park, Hye-Rim, et al.
Publicado: (2003)

Expression of osteoprotegerin and its ligands, RANKL and TRAIL, in rheumatoid arthritis
por: Remuzgo-Martínez, Sara, et al.
Publicado: (2016)

716. In vitro and In vivo Nonclinical Efficacy of AR-501 (Gallium Citrate)
por: Woo, Jennifer, et al.
Publicado: (2019)

An In Vitro Comparison of PMMA and Calcium Sulfate as Carriers for the Local Delivery of Gallium(III) Nitrate to Staphylococcal Infected Surgical Sites
por: Garcia, Rebecca A., et al.
Publicado: (2016)

The Mechanism of Osteoprotegerin-Induced Osteoclast Pyroptosis In Vitro
por: Zhu, Jiaqiao, et al.
Publicado: (2023)

Effects of High and Low Doses of Folic Acid on the Soluble Receptor Activator of Nuclear Factor-kappa B Ligand/Osteoprotegerin Ratio during Pregnancy
por: FATHI MAROUFI, Nazila, et al.
Publicado: (2017)

Paeoniflorin Inhibits Receptor Activator for Nuclear Factor κB (RANK) Ligand-Induced Osteoclast Differentiation In Vitro and Particle-Induced Osteolysis In Vivo
por: Li, Zhuokai, et al.
Publicado: (2018)

Receptor activator of nuclear factor kB ligand, osteoprotegerin, and risk of death following a breast cancer diagnosis: results from the EPIC cohort
por: Sarink, Danja, et al.
Publicado: (2018)

Osteoprotegerin/Receptor Activator of Nuclear Factor-Kappa B Ligand/Receptor Activator of Nuclear Factor-Kappa B Axis in Obesity, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease
por: Vachliotis, Ilias D., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3uflb0nfn2o1qc4k5kj7cu7vs2